FDA Class II Recall: The Harvard Drug Group LLC's Omega-3-Acid Ethyl Esters Capsules Fail Quality Specifications
The Harvard Drug Group LLC has initiated a Class II recall for Omega-3-Acid Ethyl Esters Capsules due to out-of-specification Loss on Drying. This nationwide recall, impacting 2,238 cartons, necessitates immediate supply chain review and quality assurance reassessment for procurement directors and regulatory affairs heads, highlighting critical compliance risks for this essential cardiovascular therapy.
FDA Class II Recall: Omega-3-Acid Ethyl Esters by The Harvard Drug Group LLC
The Harvard Drug Group LLC, based in Dublin, OH, has initiated a Class II recall (D-0493-2026) for 2,238 cartons of its Omega-3-Acid Ethyl Esters Capsules, USP, 1 gram. This voluntary, firm-initiated action, reported to the FDA on April 29, 2026, stems from critical quality failures where routine stability testing revealed out-of-specification results for Loss on Drying of the capsule shells. The product, packaged and distributed by Major Pharmaceuticals, Indianapolis, IN, under NDC 0904-7495-06, was distributed nationwide across the USA. For procurement directors and supply chain VPs, this means immediate action is required to quarantine and return affected lots N02406 (Exp 10/31/2026) and N02845 (Exp 12/31/2026). The Class II classification indicates that the product may cause temporary or medically reversible adverse health consequences, or that the probability of serious adverse health consequences is remote. The ongoing status of this recall necessitates continuous monitoring of FDA updates and a proactive assessment of inventory exposure to prevent distribution of non-compliant product, ensuring patient safety and regulatory adherence.
Quality Deficiency Analysis: Out-of-Specification Loss on Drying for Capsule Shells
The core issue driving this recall is the failure of capsule shells to meet Loss on Drying (LoD) specifications during routine stability testing. LoD measures the amount of volatile matter, primarily water, within a substance. For pharmaceutical capsule shells, maintaining precise moisture content is paramount for structural integrity, mechanical strength, and the protection of the encapsulated drug substance. Out-of-specification LoD results suggest that the capsule shells either contained too much moisture, potentially compromising the stability of the Omega-3-Acid Ethyl Esters, or too little, leading to brittleness and potential cracking. For regulatory affairs heads, this raises concerns about the long-term stability and efficacy of the Omega-3-Acid Ethyl Esters, which are susceptible to oxidation. A compromised capsule shell could expose the active pharmaceutical ingredient (API) to environmental factors, accelerating degradation and potentially reducing therapeutic benefit or forming harmful impurities. Business development executives must recognize that such fundamental quality control failures can erode market trust and necessitate a comprehensive review of quality assurance protocols for all outsourced packaging and distribution partners.
Supply Chain and Commercial Impact of Nationwide Distribution
The nationwide distribution of 2,238 cartons of affected Omega-3-Acid Ethyl Esters Capsules presents significant logistical and commercial challenges. This volume, spread across the USA, means pharmacies, hospitals, and other healthcare providers are likely holding affected stock from lots N02406 (Exp 10/31/2026) and N02845 (Exp 12/31/2026). Procurement directors must immediately identify and quarantine these specific lots to prevent further distribution and ensure compliance. The recall's scope underscores the critical need for robust traceability systems within the supply chain. Companies sourcing this product from Major Pharmaceuticals or The Harvard Drug Group LLC face immediate supply disruptions, potentially requiring expedited sourcing from alternative suppliers, which can incur higher costs and longer lead times for qualification. This event serves as a stark reminder for supply chain VPs to diversify their supplier base for critical generic pharmaceuticals like Omega-3-Acid Ethyl Esters and to implement rigorous, ongoing quality audits to mitigate the risk of similar, costly disruptions.
Navigating Ongoing Recall Status and Future Regulatory Scrutiny
The FDA's classification of this as an 'Ongoing' Class II recall means that The Harvard Drug Group LLC is actively engaged in the recall process, including notifying customers, retrieving affected product, and ensuring proper disposition. While this recall was firm-initiated and voluntary, the FDA will rigorously oversee the effectiveness of these actions. Regulatory affairs teams should anticipate that the FDA will require a thorough root cause analysis of the out-of-specification LoD results and a comprehensive plan for corrective and preventive actions (CAPA). Failure to adequately address these underlying quality system deficiencies could lead to further regulatory scrutiny, including potential official actions. This incident, alongside other recent Class II recalls such as Essential Wellness Pharma's Progesterone Injection and Spectra Medical Devices' Lidocaine HCl Injection, highlights a broader industry challenge in maintaining consistent product quality. Business development executives must consider the reputational impact of such recalls and the potential for increased regulatory oversight, which could affect future product approvals and market access for firms with a history of quality issues.